Pheochromocytoma (PHEO) and Paraganglioma (PGL)
1
Section on Medical Neuroendocrinology, Head, Developmental Endocrine Oncology and Genetics Affinity Group. Eunice Kennedy Shriver NICHD, NIH, Building 10, CRC, Room 1E-3140, 10 Center Drive MSC-1109, Bethesda, MD 20892-1109, USA
2
Department of Nuclear Medicine, La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, 13100 Marseille, France
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(9), 1391; https://doi.org/10.3390/cancers11091391
Received: 9 September 2019 / Accepted: 16 September 2019 / Published: 18 September 2019
(This article belongs to the Special Issue Pheochromocytoma (PHEO) and Paraganglioma (PGL))
Note: In lieu of an abstract, this is an excerpt from the first page.
This series of 23 articles (17 original articles, six reviews) is presented by international leaders in pheochromocytoma and paraganglioma (PPGL) [...] View Full-Text
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Pacak, K.; Taïeb, D. Pheochromocytoma (PHEO) and Paraganglioma (PGL). Cancers 2019, 11, 1391. https://doi.org/10.3390/cancers11091391
AMA Style
Pacak K, Taïeb D. Pheochromocytoma (PHEO) and Paraganglioma (PGL). Cancers. 2019; 11(9):1391. https://doi.org/10.3390/cancers11091391
Chicago/Turabian StylePacak, Karel; Taïeb, David. 2019. "Pheochromocytoma (PHEO) and Paraganglioma (PGL)" Cancers 11, no. 9: 1391. https://doi.org/10.3390/cancers11091391
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit
